JP Morgan Chase
ADPT icon

JP Morgan Chase’s Adaptive Biotechnologies ADPT Stock Holding History

JP Morgan Chase’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-108,000
Closed -$4.35M – 6308
2021
Q1 		$4.35M Buy
+108,000
New +$5.85M ﹤0.01% 3091

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase's ADPT Position: Q2 2026 in Review

JP Morgan Chase increased its Adaptive Biotechnologies (ADPT) stake by 88% in Q2 2026, buying an estimated $3.51M and bringing the position to 488,395 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

JP Morgan Chase first reported a position in ADPT in Q2 2019 and has held it in 29 quarters since. The position peaked at $78.4M in Q4 2020. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • JP Morgan Chase held 488,395 shares of Adaptive Biotechnologies worth $10.6M as of Q2 2026.
  • JP Morgan Chase bought 229,219 Adaptive Biotechnologies shares in Q2 2026, an estimated $3.51M.
  • Adaptive Biotechnologies made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2750 holding.
  • JP Morgan Chase first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 29 quarters since.
  • JP Morgan Chase's Adaptive Biotechnologies position peaked at $78.4M in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.